Search: onr:"swepub:oai:DiVA.org:uu-83482" > Omega-3 fatty acid ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05706naa a2200505 4500 | |
001 | oai:DiVA.org:uu-83482 | |
003 | SwePub | |
008 | 061103s2006 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-74167 | |
009 | oai:prod.swepub.kib.ki.se:1943575 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-834822 URI |
024 | 7 | a https://doi.org/10.1001/archneur.63.10.14022 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-741672 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19435752 URI |
040 | a (SwePub)uud (SwePub)orud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Freund-Levi, Yvonne,d 1956-u Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 aut0 (Swepub:oru)yfi |
245 | 1 0 | a Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease :b OmegAD study - A randomized double-blind trial |
264 | 1 | b American Medical Association (AMA),c 2006 |
338 | a print2 rdacarrier | |
520 | a Background: Epidemiologic and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids, for example, docosahexaenoic acid and eicosapentaenoic acid, may prevent Alzheimer disease (AD). Objective: To determine effects of dietary omega-3 fatty acid supplementation on cognitive functions in patients with mild to moderate AD. Design: Randomized, double-blind, placebo-controlled clinical trial. Participants: Two hundred four patients with AD (age range [mean +/- SD], 74 +/- 9 years) whose conditions were stable while receiving acetylcholine esterase inhibitor treatment and who had a Mini-Mental State Examination (MMSE) score of 15 points or more were randomized to daily intake of 1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid (omega-3 fatty acid-treated group) or placebo for 6 months, after which all received omega-3 fatty acid supplementation for 6 months more. Main Outcome Measures: The primary outcome was cognition measured with the MMSE and the cognitive portion of the Alzheimer Disease Assessment Scale. The secondary outcome was global function as assessed with the Clinical Dementia Rating Scale; safety and tolerability of omega-3 fatty acid supplementation; and blood pressure determinations. Results: One hundred seventy-four patients fulfilled the trial. At baseline, mean values for the Clinical Dementia Rating Scale, MMSE, and cognitive portion of the Alzheimer Disease Assessment Scale in the 2 randomized groups were similar. At 6 months, the decline in cognitive functions as assessed by the latter 2 scales did not differ between the groups. However, in a subgroup (n=32) with very mild cognitive dysfunction (MMSE > 27 points), a significant (P <.05) reduction in MMSE decline rate was observed in the omega-3 fatty acid-treated group compared with the placebo group. A similar arrest in decline rate was observed between 6 and 12 months in this placebo subgroup when receiving omega-3 fatty acid supplementation. The omega-3 fatty acid treatment was safe and well tolerated. Conclusions: Administration of omega-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale. However, positive effects were observed in a small group of patients with very mild AD (MMSE > 27 points). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Eriksdotter-Jonhagen, Mariau Karolinska Institutet4 aut |
700 | 1 | a Cederholm, Tommyu Karolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)tomce419 |
700 | 1 | a Basun, Hansu Uppsala universitet,Geriatrik,Division of Geriatrics, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)habas169 |
700 | 1 | a Faxén-Irving, Gerdu Karolinska Institutet4 aut |
700 | 1 | a Garlind, Anitau Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 aut |
700 | 1 | a Vedin, Ingeru Karolinska Institutet4 aut |
700 | 1 | a Vessby, Bengtu Uppsala universitet,Klinisk nutrition och metabolism,Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)bengvess |
700 | 1 | a Wahlund, Lars-Olofu Karolinska Institutet4 aut |
700 | 1 | a Palmblad, Janu Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden4 org |
773 | 0 | t Archives of Neurologyd : American Medical Association (AMA)g 63:10, s. 1402-1408q 63:10<1402-1408x 0003-9942x 1538-3687 |
856 | 4 | u https://jamanetwork.com/journals/jamaneurology/articlepdf/792554/noc60062.pdf |
856 | 4 | u https://doi.org/10.1001/archneur.63.10.1402y Fulltext |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-83482 |
856 | 4 8 | u https://doi.org/10.1001/archneur.63.10.1402 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74167 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1943575 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view